Related Experiment Videos
Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor
P G Stalboerger1, C J Panetta, R D Simari
1Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
Plasmin is an important protease that mediates clot fibrinolysis and vessel wall extracellular matrix proteolysis. Recently, in vitro studies have suggested that plasmin can cleave and inactivate recombinant TFPI, a major inhibitor of TF-mediated coagulation. We hypothesized that such an interaction may occur in vascular cells expressing TFPI, or in the vessel wall, with implications for thrombolysis. In a series of experiments, we examined the effects of plasmin on cell surface and extracellular matrix (ECM) associated TFPI in endothelial cells (EC) in culture and on EC and smooth muscle cells (SMC) in the vessel wall. Plasmin (0.2 microM) decreased cell surface and matrix associated TFPI activity in cultured endothelial cells by 77 +/- 5% and 69 +/- 6% respectively (p < 0.01). Plasminogen, the proenzyme form of plasmin had no such effect on cell surface TFPI or matrix TFPI. Cell surface TFPI antigen measured by fluorescence activated cell sorter (FACS) was also significantly reduced by plasmin. Proteolysis of conditioned medium TFPI was suggested by loss of a approximately 45kD TFPI on Western Blot analysis following plasmin treatment. Plasmin also proteolysed a approximately 45kD TFPI protein in the intact ECM of EC, an effect which was inhibited by preincubation with aprotinin, a plasmin inhibitor. Incubation of similar concentrations of plasmin, with homogenates of normal vessel decreased a approximately 45kD TFPI immunoreactive band on Western blot analysis. Plasmin also decreased surface TFPI activity on frozen sections of normal vessel as measured by an amidolytic assay. Finally, plasmin treatment of atherosclerotic plaque sections caused complete removal of TFPI immunoreactivity associated with luminal EC and intimal SMC, when compared to control treated plaque (n = 3). Together these data suggest that plasmin proteolyses the majority of EC-associated (surface and matrix) TFPI and may remove TFPI from the luminal surface and intima of the vessel wall. TFPI proteolysis in cultured EC was associated with significant reduction in TFPI anticoagulant activity. These data provide evidence that plasmin degradation of TFPI occurs in vascular cells and in the vessel wall and may have implications for re-thrombosis following thrombolysis in vivo.
Insights
Plasmin degrades tissue factor pathway inhibitor (TFPI) in vascular cells and the vessel wall. This proteolysis reduces TFPI
Area of Science:
- Biochemistry
- Vascular Biology
- Hemostasis and Thrombosis
Background:
- Plasmin is a key protease in fibrinolysis and extracellular matrix remodeling.
- In vitro studies suggest plasmin inactivates tissue factor pathway inhibitor (TFPI).
- The in vivo relevance of plasmin's effect on TFPI in vascular cells and the vessel wall is unclear.
Purpose of the Study:
- To investigate the effect of plasmin on cell surface and extracellular matrix (ECM)-associated TFPI.
- To examine plasmin's impact on TFPI in cultured endothelial cells (EC) and in the vessel wall.
- To assess the implications of plasmin-mediated TFPI degradation for coagulation and thrombolysis.
Main Methods:
- Experiments using cultured EC and smooth muscle cells (SMC).
- Treatment with plasmin and plasminogen.
- Assays included amidolytic activity, fluorescence-activated cell sorting (FACS), Western blotting, and analysis of vessel wall and atherosclerotic plaque sections.
Main Results:
- Plasmin significantly reduced TFPI activity and antigen on EC surfaces and in ECM.
- Plasmin proteolyzed TFPI in cultured cells, vessel wall homogenates, and atherosclerotic plaques.
- TFPI degradation by plasmin was associated with reduced anticoagulant activity.
Conclusions:
- Plasmin proteolyses TFPI in vascular cells and the vessel wall.
- This degradation removes TFPI from EC surfaces and the vessel intima.
- Plasmin-mediated TFPI degradation may impact re-thrombosis risk after thrombolysis.